Metropolis Healthcare Limited
NSE: METROPOLISHealthcare Service Provider
Share price
₹529.25
+0.65% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
68
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹10,909 Cr
P/E ratio
51.6
P/B ratio
7.2
ROCE
17.8%
ROE
13.6%
Dividend yield
0.4%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 21.8% over the past year, and 10.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 26.1% to 24.7% over the last four years.
Whether it grew faster than its sector
It grew 10.0% a year against a sector median of 13.1% — 3.1 percentage points slower.
Room to re-rate, or risk of de-rating
At 51.6× earnings it costs 2.2× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 56.7×, across 5 companies. It is against its own five-year median of 57.6×, the 29th percentile of its own range.
Whether growth justifies the valuation
Priced at 4.7 times its growth rate, on earnings growth of 11%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Metropolis Healthcare Limited — this one | 11%/yr | 51.6× | ₹4.7 |
| Dr. Lal Path Labs Ltd. | 30%/yr | 56.7× | ₹1.9 |
| Vijaya Diagnostic Centre Limited | 24%/yr | 76.5× | ₹3.2 |
| Thyrocare Technologies Limited | 36%/yr | 44.3× | ₹1.2 |
| Nephrocare Health Services Limited | 103%/yr | 73.7× | — |
| Krsnaa Diagnostics Limited | 18%/yr | 17.5× | ₹0.97 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 8 of 12 on returns, 11 of 11 on growth, 9 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 17.8% on capital, ahead of 33% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹1378 crore of cash from the business, spent ₹264 crore on plant and equipment, and returned ₹512 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 141 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being paid 26 days before it paid its own suppliers to paid 15 days before it paid its own suppliers.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
9 of 9 checks clear · 100%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue grew about 17% and profit margin reached 25.2%, ahead of the growth and margin-improvement run rate management had set.
Announced 4 Aug 2026 · Consolidated · Unaudited
Revenue
₹450 Cr
Revenue vs last year
+16.6%
Revenue vs last quarter
+5.9%
Net profit
₹57 Cr
Profit vs last year
+26.4%
Profit vs last quarter
+11.5%
Net margin
12.6%
EPS
₹2.73
Earnings call transcript · 5 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹10,909 Cr
- Prev close
- ₹529.25
- 52w High
- ₹609
- 52w Low
- ₹412
- Enterprise value
- ₹10,809 Cr
- Beta
- 0.6
- Price CAGR 1y
- 7.0%
- Price CAGR 3y
- 13.0%
- Price CAGR 5y
- -5.0%
- Price CAGR 10y
- —
Ratios
- Return on assets
- 9.0%
- PEG ratio
- 4.8
- P/E ratio
- 51.6
- P/B ratio
- 7.2
- EV / EBITDA
- 25.6
- Industry P/E
- 44.1
- ROCE
- 17.8%
- ROCE 5y average
- 19.0%
- ROE
- 13.6%
- Debt / Equity
- 0.2
- Interest coverage
- 9.9
- Dividend yield
- 0.4%
- ROE 3y average
- 12.0%
- ROE last year
- 14.0%
Annual P&L
- Annual revenue
- ₹1,646 Cr
- Annual profit
- ₹191 Cr
- Operating margin
- 25.0%
- Net profit margin
- 11.6%
- EBITDA margin
- 24.7%
- Sales growth 3y
- 12.8%
- Sales growth 5y
- 10.5%
- Profit growth 3y
- 11.0%
- Profit growth 5y
- 1.0%
- EPS
- ₹9.2
- Sales growth TTM
- 22.0%
- Profit growth TTM
- 37.0%
- Dividend payout
- 55.0%
Quarter P&L
- Sales latest quarter
- ₹450 Cr
- Profit latest quarter
- ₹57 Cr
- YoY quarterly sales growth
- 16.6%
- YoY quarterly profit growth
- 26.7%
- OPM latest quarter
- 24.7%
Balance Sheet
- Book Value
- ₹73.8
- Face Value
- ₹2.0
- Total debt
- ₹232 Cr
- Total cash
- ₹62 Cr
- Borrowings
- ₹232 Cr
- Reserves / Equity
- 35.9
Cash Flow
- Operating cash flow
- ₹351 Cr
- Free cash flow
- ₹300 Cr
- FCF yield
- 2.5%
- Net cash flow
- ₹15 Cr
Shareholding
- Promoter holding
- 48.9%
- FII holding
- 11.0%
- DII holding
- 35.1%
- Public holding
- 5.0%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | 1,915.00 | 57.1 | 32,143 | 0.73 | 170.5 | 28.0 | 797.7 | 19.1 | 28.0 |
| Vijaya Diagnost. | 1,440.60 | 79.2 | 14,838 | 0.14 | 53.1 | 37.6 | 231.0 | 22.8 | 20.5 |
| Metropolis Healt | 533.00 | 53.1 | 11,057 | 0.37 | 56.9 | 25.8 | 450.2 | 16.6 | 17.8 |
| Thyrocare Tech. | 504.25 | 44.4 | 8,026 | 1.82 | 51.3 | 34.1 | 240.0 | 24.3 | 35.4 |
| Nephrocare Health Services | 625.35 | 73.9 | 6,288 | 0.00 | 32.0 | 34.9 | 281.8 | 23.7 | 15.3 |
| Krsnaa Diagnost. | 535.85 | 17.6 | 1,738 | 0.37 | 15.8 | -19.1 | 210.7 | 19.9 | 12.7 |
| Suraksha Diagno. | 312.75 | 45.5 | 1,629 | 0.16 | 12.9 | 38.4 | 87.7 | 20.8 | 17.3 |
| Median | 319.95 | 32.5 | 1,124 | 0.00 | 11.0 | 28.0 | 95.2 | 19.1 | 20.5 |
Competes with: 3B Blackbio Dx Limited, Dr. Lal Path Labs Ltd., Gaudium IVF and Women Health Limited, Health X Platform Limited, Krsnaa Diagnostics Limited, Molbio Diagnostics Limited, Nephrocare Health Services Limited, One Global Service Provider Limited, Pramodini Medicare Limited, Sastasundar Ventures Limited, Suraksha Diagnostic Limited, Thyrocare Technologies Limited, Vijaya Diagnostic Centre Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 277 | 309 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 |
| Expenses | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 311 | 317 | 339 |
| Material Cost | 72 | 79 | 88 | 79 | 78 | 87 | |||||||
| Change in Inventories | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Employee Cost | 82 | 92 | 95 | 94 | 95 | 107 | |||||||
| Other Expenses | 129 | 125 | 138 | 138 | 143 | 145 | |||||||
| Operating Profit | 63 | 75 | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 | 95 | 108 | 111 |
| OPM % | 23 | 24 | 22 | 24 | 25 | 26 | 22 | 18 | 23 | 25 | 23 | 25 | 25 |
| Other Income | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 | -0 | 8 | 5 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | -9.10 | 0.11 | 0 | |||||||
| Interest | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 6 |
| Depreciation | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 | 39 | 32 |
| Profit before tax | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 | 70 | 78 |
| Tax % | 26 | 26 | 26 | 28 | 25 | 24 | 26 | 19 | 26 | 26 | 26 | 27 | 27 |
| Net Profit | 29 | 36 | 27 | 37 | 38 | 47 | 31 | 29 | 45 | 53 | 42 | 51 | 57 |
| EPS in Rs | 1.41 | 1.73 | 1.33 | 1.78 | 1.85 | 2.27 | 1.53 | 1.41 | 2.17 | 2.54 | 2 | 2.46 | 2.73 |
| Diluted EPS in Rs | 5.66 | 8.66 | 10 | 7.94 | 2.46 | 2.73 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 456 | 475 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 | 1,710 |
| Expenses | 339 | 359 | 405 | 467 | 559 | 619 | 708 | 880 | 855 | 920 | 1,023 | 1,240 | 1,288 |
| Material Cost | 269 | 325 | |||||||||||
| Change in Inventories | 0 | 0 | |||||||||||
| Purchases of Stock-in-Trade | 0 | 0 | |||||||||||
| Employee Cost | 314 | 377 | |||||||||||
| Other Expenses | 446 | 543 | |||||||||||
| Operating Profit | 117 | 116 | 140 | 181 | 203 | 237 | 290 | 348 | 293 | 288 | 308 | 406 | 422 |
| OPM % | 26 | 24 | 26 | 28 | 27 | 28 | 29 | 28 | 26 | 24 | 23 | 25 | 25 |
| Other Income | 7 | 29 | 39 | 6 | 8 | -17 | 12 | 34 | 15 | 9 | 15 | 16 | 14 |
| Exceptional items (within Other Income) | 0 | -8.99 | |||||||||||
| Interest | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 | 24 | 29 | 26 |
| Depreciation | 21 | 17 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 | 109 | 134 | 135 |
| Profit before tax | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 | 191 | 259 | 276 |
| Tax % | 33 | 36 | 33 | 32 | 34 | 24 | 25 | 27 | 24 | 26 | 24 | 26 | |
| Net Profit | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 | 146 | 191 | 203 |
| EPS in Rs | 15 | 20 | 27 | 27 | 5.99 | 6.29 | 8.95 | 10 | 6.98 | 6.24 | 7 | 9.17 | 9.73 |
| Diluted EPS in Rs | 28 | 9.19 | |||||||||||
| Dividend Payout % | 0 | 100 | 49 | 0 | 55 | 32 | 22 | 19 | 29 | 16 | 0 | 55 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 13%
- 5 years
- 11%
- 3 years
- 13%
- TTM
- 22%
Compounded profit growth
- 10 years
- 11%
- 5 years
- 1%
- 3 years
- 11%
- TTM
- 37%
Stock price CAGR
- 10 years
- —
- 5 years
- -5%
- 3 years
- 13%
- 1 year
- 7%
Return on equity
- 10 years
- 19%
- 5 years
- 15%
- 3 years
- 12%
- Last year
- 14%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 41 |
| Reserves | 352 | 269 | 314 | 405 | 408 | 513 | 696 | 876 | 978 | 1,086 | 1,321 | 1,472 |
| Borrowings | 14 | 5 | 1 | 1 | 18 | 67 | 112 | 379 | 266 | 197 | 204 | 232 |
| Other Liabilities | 87 | 107 | 188 | 110 | 113 | 160 | 181 | 256 | 240 | 254 | 324 | 386 |
| Minority Interest | 3.67 | 11 | ||||||||||
| Total Liabilities | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,859 | 2,131 |
| Fixed Assets | 153 | 142 | 202 | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 | 1,601 |
| CWIP | 0 | 1 | 1 | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 | 0 |
| Investments | 168 | 101 | 142 | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 | 142 |
| Other Assets | 141 | 147 | 167 | 216 | 298 | 437 | 647 | 440 | 340 | 316 | 341 | 387 |
| Total Assets | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,867 | 2,138 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 69 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 | 351 |
| Cash from Investing Activity | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 | -220 |
| Cash from Financing Activity | -9 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 | -115 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 | 15 |
| Free Cash Flow | 46 | 79 | 45 | 90 | 67 | 179 | 221 | 223 | 195 | 200 | 196 | 300 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 54 | 54 | 57 | 66 | 55 | 45 | 40 | 39 | 38 | 41 | 38 |
| Inventory Days | 52 | 46 | 38 | 53 | 55 | 44 | 59 | 68 | 64 | 58 | 65 | 51 |
| Days Payable | 92 | 96 | 97 | 88 | 90 | 152 | 160 | 136 | 136 | 150 | 171 | 146 |
| Cash Conversion Cycle | 17 | 3 | -5 | 21 | 30 | -54 | -56 | -29 | -33 | -53 | -65 | -57 |
| Working Capital Days | 32 | 8 | -27 | 28 | 33 | 2 | -9 | -26 | -22 | -16 | -18 | -15 |
| ROCE % | 28 | 34 | 46 | 43 | 43 | 40 | 36 | 29 | 17 | 16 | 15 | 18 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
29.35inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
30,45,209inr
2026-03-31
volume growth %
11.00pct
2026-06-30
News
News and filings about Metropolis Healthcare Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
- 3B Blackbio Dx Limited
- Dr. Lal Path Labs Ltd.
- Gaudium IVF and Women Health Limited
- Health X Platform Limited
- Krsnaa Diagnostics Limited
- Molbio Diagnostics Limited
- Nephrocare Health Services Limited
- One Global Service Provider Limited
- Pramodini Medicare Limited
- Sastasundar Ventures Limited
- Suraksha Diagnostic Limited
- Thyrocare Technologies Limited
- Vijaya Diagnostic Centre Limited
Uses as raw material
- diagnostic reagents
- diagnostic test kits
- laboratory chemicals
- medicines and laboratory consumables
Buys from
- Tarsons Products Limited · Plastic labware — specimen containers, tubes (diagnostics)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Healthcare Service Provider
- Classification
- Healthcare › Healthcare Service Provider
- ISIN
- INE112L01020
News impact
Big market events that reach Metropolis Healthcare Limited, and how the effect spreads.
24 Sept, 11:36 IST · Market event · high impact
Nephrocare shares tumble 5% | What’s driving the decline?
Large holders are selling about Rs 650 crore of kidney-care firm Nephrocare at a 5% discount, hurting current shareholders short-term while letting new buyers enter cheaper.
Who it hits first
- Nephrocare Health Services, which runs kidney dialysis clinics, fell over 5% after reports that large holders want to sell about Rs 650 crore of shares at Rs 705 each.
- That Rs 705 price is about 5% below the last close of Rs 741.90, so the market is repricing toward the cheaper deal price.
- The business itself is unchanged — only the shareholding is shifting.
Who may gain
- Buyers who get the block at Rs 705 gain an instant 5% discount to the Rs 741.90 close.
- Patient investors who wanted Nephrocare shares can now buy the dip if the fall overdoes the discount.
Along the supply chain
Downstream
No direct downstream impact — hospitals it serves, including Max Healthcare, Fortis Healthcare, and Medanta, see no change to orders or contracts from this share sale.
Upstream
No direct supply-chain link upstream — Nephrocare lists no suppliers in the pack, and a shareholder sale does not change what it buys.
Where demand moves
Business
No change to patient visits, dialysis sessions, or clinic revenue — the Rs 650 crore sale moves existing shares between investors, not customers.
Capital
About Rs 650 crore of new share supply near Rs 705 pulls the price down short-term as traders sell; bargain hunters absorbing the block provide the offsetting buy flow.
How it spreads across sectors
Healthcare
No sector-wide impact — a single-company share sale with no change to hospital or lab demand; peers should trade flat.
When it plays out
Immediate
1–7 days: Nephrocare trades heavy near Rs 705 as the Rs 650 crore block clears; peers flat.
Medium term
1–6 months: price follows clinic results again, not the block; no lasting sector effect.
Short term
1–4 weeks: discount overhang fades if buyers hold; price stabilises unless more selling appears.
17 Sept, 10:43 IST · Market event · high impact
Krsnaa Diagnostics share price jumps 11%: Stock in focus after company enters PET-CT segment
Krsnaa Diagnostics won a 15-year Punjab deal to run costly PET-CT cancer scans, so its shares jumped 11% on years of expected scan income, while rival lab chains gain nothing directly.
Who it hits first
- Krsnaa Diagnostics won a 15-year Punjab government deal to run PET-CT cancer-imaging scans, opening a costly high-value scan business it did not have before.
- The stock jumped 11% as investors priced in years of steady scan income from the long contract.
Who may gain
- Krsnaa Diagnostics gains a 15-year revenue stream and a new high-value PET-CT line; no listed peer shares the award.
Along the supply chain
Downstream
Punjab government hospitals and patients get advanced cancer imaging locally instead of referring cases out.
Upstream
PET-CT scanners come from unlisted global makers (Siemens, GE, Philips) and tracer supply has no listed pure-play, so no listed upstream impact.
Where demand moves
Business
Punjab's public hospitals will send PET-CT scan demand to Krsnaa's new centres for 15 years; scanner makers and tracer suppliers are unlisted so no listed upstream benefit.
Capital
Money rotates into KRSNAA shares on the repricing; no sector-wide rotation since the award is exclusive to one company.
How it spreads across sectors
Healthcare
Mild positive: validates the PPP route for high-end diagnostics and hints other states may tender similar PET-CT deals.
When it plays out
Immediate
Shares already up 11%; follow-through depends on disclosed order value and rollout plan.
Medium term
Scan volumes and revenue/margin contribution from PET-CT over 1-6 months and beyond.
Short term
Agreement signing, centre commissioning schedule, and management commentary in quarterly results.
13 May, 04:18 IST · Market event · high impact
Apex chemist body calls nationwide shutdown protesting 'deep discounts' of e-pharmacies
Who it hits first
- AIOCD shutdown disrupts physical pharmacy access
- E-pharmacies face regulatory scrutiny pressure
- MEDPLUS in regulatory crossfire
- APOLLOHOSP in-house pharmacy may gain refill volumes
Who may gain
- Organized chemists if discount caps imposed
- Pharma manufacturers if MRP enforcement strengthens
- Hospital chains with in-house pharmacy
Along the supply chain
Downstream
Patient access disruption; chronic-care risk; insurance claims may rise
Upstream
Pharma manufacturers (Sun, Cipla, Lupin) — insulated as MRP intact
Where demand moves
Business
Physical pharmacy shutdown shifts volumes to e-pharm short-term. Longer-term regulatory caps reverse flow to organized retail.
Capital
Sector uncertainty discount. Capital prefers manufacturer-led pharma.
How it spreads across sectors
Consumer Services
E-pharm growth slowdown if caps imposed
Healthcare
Patient access risk
Pharma Retail
Regulatory uncertainty premium
codex additions
When it plays out
Immediate
MEDPLUS flat-to-negative (pledge); APOLLOHOSP flat
Medium term
Regulatory caps reshape pharma retail margins
Short term
NPPA/CDSCO commentary critical
Other sectors it reaches
- {"causal_chain":"E-pharmacy order volumes and store shutdown disruption affect medicine fulfillment, hyperlocal delivery density, cold-chain handling, and reverse logistics demand.","direction":"mixed","example_tickers":["DELHIVERY","TCIEXP","VRLLOG"],"magnitude":"medium","notes":"Negative if regulatory pressure reduces e-pharmacy growth; positive short-term if consumers shift to online during physical-store shutdowns.","sector":"Logistics \u0026 Last-Mile Delivery","time_horizon":"immediate"}
- {"causal_chain":"Any shift from offline pharmacy cash/card purchases to app-based medicine ordering increases UPI/card/wallet payment flows; discount caps could slow e-pharmacy transaction growth later.","direction":"mixed","example_tickers":["PAYTM","POLICYBZR","INFIBEAM"],"magnitude":"small","notes":"Listed pure-play exposure is limited; impact is more volume-sentiment than earnings material.","sector":"Digital Payments \u0026 Fintech","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"E-pharmacy apps often cross-sell diagnostics, subscriptions, and chronic-care packages; regulatory pressure on their core pharmacy funnel can affect lead generation for diagnostics.","direction":"negative","example_tickers":["LALPATHLAB","METROPOLIS","VIJAYA"],"magnitude":"small","notes":"Most listed diagnostics firms are not dependent on e-pharmacy, but digital acquisition partnerships could be affected.","sector":"Diagnostics \u0026 Preventive Health Platforms","time_horizon":"1_to_6_months"}
- {"causal_chain":"Patient access disruption at retail chemists may divert some medicine purchases and refills to hospital pharmacies, while Apollo faces scrutiny because it operates both hospital and pharmacy channels.","direction":"mixed","example_tickers":["APOLLOHOSP","MAXHEALTH","FORTIS"],"magnitude":"small","notes":"Potential footfall benefit for hospital pharmacies, offset by headline/regulatory risk for integrated players.","sector":"Hospital Chains With Outpatient Pharmacy/Diagnostics","time_horizon":"immediate"}
- {"causal_chain":"Medicine affordability and chronic prescription adherence are relevant for claims experience; discount caps may raise patient out-of-pocket costs, while shutdowns can disrupt medicine access.","direction":"negative","example_tickers":["STARHEALTH","NIACL","ICICIGI"],"magnitude":"small","notes":"Likely indirect and slow-moving; more relevant if policy action materially raises recurring medicine costs.","sector":"Insurance \u0026 Health Benefit Platforms","time_horizon":"1_to_6_months"}
- {"causal_chain":"Regulatory pressure on e-pharmacies can increase demand for compliance systems, prescription validation, inventory traceability, and digital audit infrastructure across pharmacy networks.","direction":"positive","example_tickers":["TCS","INFY","LTIM"],"magnitude":"small","notes":"Large IT firms have diversified revenue, so stock impact is modest, but compliance-tech spending could rise.","sector":"IT Services / Healthtech Implementation","time_horizon":"1_to_6_months"}
- {"causal_chain":"Pharmacies also sell OTC, nutraceutical, personal care, and wellness products; shutdowns disrupt channel sales, while discount regulation may alter online-offline channel economics.","direction":"mixed","example_tickers":["HINDUNILVR","DABUR","MARICO"],"magnitude":"small","notes":"Impact is limited because these companies have broad distribution beyond chemists.","sector":"FMCG / OTC Wellness Distribution","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"If regulators curb e-pharmacy discounts, organized offline pharmacy formats and neighborhood chemists gain durability, supporting pharmacy store economics and retail occupancy demand.","direction":"positive","example_tickers":["PHOENIXLTD","BRIGADE","PRESTIGE"],"magnitude":"small","notes":"Second-order effect; strongest only if offline retail economics structurally improve.","sector":"Commercial Real Estate / Retail Leasing","time_horizon":"1_to_6_months"}
- {"causal_chain":"E-pharmacy apps rely on mobile ordering, digital prescriptions, and customer engagement; any accelerated online migration during shutdowns increases app traffic, while future discount caps could reduce engagement intensity.","direction":"mixed","example_tickers":["BHARTIARTL","IDEA","INDUSTOWER"],"magnitude":"small","notes":"Causal link exists but earnings sensitivity is negligible for large telecom names.","sector":"Telecom \u0026 Data Consumption","time_horizon":"immediate"}
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 19 May 2026 | interim | ₹1 |
|---|---|---|
| 20 Mar 2026 | bonus | ₹0 |
| 11 Nov 2025 | interim | ₹4 |
| 17 Nov 2023 | interim | ₹4 |
| 23 Feb 2023 | interim | ₹8 |
| 21 Feb 2022 | interim | ₹8 |
| 17 Feb 2021 | interim | ₹8 |
| 13 Feb 2020 | interim | ₹8 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 1, delete 1, insert 6), 2020-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2020
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 11 Aug 2026 | METZ ADVISORY LLP | SELL | 10,50,000 | ₹564.00 |
| 11 Aug 2026 | DURU SHAH FAMILY TRUST | SELL | 10,50,000 | ₹564.00 |
| 11 Aug 2026 | ADITYA BIRLA SUN LIFE MUTUAL FUND | BUY | 10,49,000 | ₹564.00 |
Insider trades
| Disclosed | Who | Type | Shares | Value ₹ Cr |
|---|---|---|---|---|
| 13 Aug 2026 | Metz Advisory LLP · Promoter | SELL | 10,50,000 | 59.22 |
| 13 Aug 2026 | Duru Shah Family Trust · Promoter Group | SELL | 10,50,000 | 59.22 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY275 Aug 2026
- Annual report · 2025-2627 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2614 May 2026
- Earnings call · Q3FY265 Feb 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.